¼¼°èÀÇ »ý¾î ½ÃÄö½Ì ½ÃÀå
Sanger Sequencing
»óǰÄÚµå : 1739366
¸®¼­Ä¡»ç : Global Industry Analysts, Inc.
¹ßÇàÀÏ : 2025³â 06¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 178 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 5,850 £Ü 8,124,000
PDF (Single User License) help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â °¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 17,550 £Ü 24,373,000
PDF (Global License to Company and its Fully-owned Subsidiaries) help
PDF º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â °¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


Çѱ۸ñÂ÷

»ý¾î ½ÃÄö½Ì ¼¼°è ½ÃÀåÀº 2030³â±îÁö 89¾ï ´Þ·¯¿¡ ´ÞÇÒ Àü¸Á

2024³â¿¡ 34¾ï ´Þ·¯·Î ÃßÁ¤µÇ´Â »ý¾î ½ÃÄö½Ì ¼¼°è ½ÃÀåÀº 2024³âºÎÅÍ 2030³â±îÁö CAGR 17.5%·Î ¼ºÀåÇÏ¿© 2030³â¿¡´Â 89¾ï ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ÀÌ º¸°í¼­¿¡¼­ ºÐ¼®ÇÑ ºÎ¹® Áß ÇϳªÀÎ ¼¦°Ç ½ÃÄö½ÌÀº CAGR 16.3%¸¦ ±â·ÏÇÏ¸ç ºÐ¼® ±â°£ Á¾·á±îÁö 54¾ï ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. Ÿ°Ù À¯ÀüÀÚ ½ÃÄö½Ì ºÎ¹®ÀÇ ¼ºÀå·üÀº ºÐ¼® ±â°£ µ¿¾È CAGR 19.1%·Î ÃßÁ¤µË´Ï´Ù.

¹Ì±¹ ½ÃÀåÀº 8¾ï 9,420¸¸ ´Þ·¯·Î ÃßÁ¤, Áß±¹Àº CAGR 16.6%·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹Ãø

¹Ì±¹ÀÇ »ý¾î ½ÃÄö½Ì ½ÃÀåÀº 2024³â¿¡ 8¾ï 9,420¸¸ ´Þ·¯·Î ÃßÁ¤µË´Ï´Ù. ¼¼°è 2À§ °æÁ¦ ´ë±¹ÀÎ Áß±¹Àº 2030³â±îÁö 14¾ï ´Þ·¯ÀÇ ½ÃÀå ±Ô¸ð¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµÇ¸ç, ºÐ¼® ±â°£ÀÎ 2024-2030³â CAGRÀº 16.6%¸¦ ±â·ÏÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ±âŸ ÁÖ¸ñÇÒ ¸¸ÇÑ Áö¿ªº° ½ÃÀåÀ¸·Î´Â ÀϺ»°ú ij³ª´Ù°¡ ÀÖ°í, ºÐ¼® ±â°£ µ¿¾È CAGRÀº °¢°¢ 15.9%¿Í 15.3%·Î ¿¹ÃøµË´Ï´Ù. À¯·´¿¡¼­´Â µ¶ÀÏÀÌ CAGR ¾à 13.0%·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

¼¼°èÀÇ "»ý¾î ½ÃÄö½Ì" ½ÃÀå - ÁÖ¿ä µ¿Çâ°ú ÃËÁø¿äÀÎ Á¤¸®

À¯ÀüüÇÐÀÌ ÁÖµµÇÏ´Â ¼¼»ó¿¡¼­ ½Ì¾î ½ÃÄö½ÌÀÌ °è¼Ó Áß¿äÇÑ ÀÌÀ¯´Â ¹«¾ùÀϱî?

Â÷¼¼´ë ½ÃÄö½Ì(NGS) Ç÷§ÆûÀÇ µîÀå¿¡µµ ºÒ±¸Çϰí, Sanger ½ÃÄö½ÌÀº Ź¿ùÇÑ Á¤È®¼º, ´Ü¼ø¼º, ƯÁ¤ ¾ÖÇø®ÄÉÀ̼ǿ¡ ´ëÇÑ ºñ¿ë È¿À²¼ºÀ¸·Î ÀÎÇØ ±× °ü·Ã¼ºÀ» À¯ÁöÇϰí ÀÖ½À´Ï´Ù. ½ÃÄö½Ì °ËÁõ, ´ÜÀÏ À¯ÀüÀÚ Áø´Ü ¹× ¼Ò±Ô¸ð ¿¬±¸ ÇÁ·ÎÁ§Æ®¿¡¼­ ¿©ÀüÈ÷ Ç¥ÁØÀ¸·Î »ç¿ëµÇ°í ÀÖ½À´Ï´Ù. ÀÌ ¹æ¹ýÀº ÀÓ»ó À¯ÀüüÇп¡¼­ ÇÏÀ̽º·çDz ¹æ¹ýÀ¸·Î È®ÀÎµÈ º¯À̸¦ È®ÀÎÇϱâ À§ÇØ ³ôÀº Æò°¡¸¦ ¹Þ°í ÀÖ½À´Ï´Ù. ½Ì¾î ½ÃÄö½ÌÀº Á¾Á¾ 1000 ¿°±â½Ö¿¡ À̸£´Â ±æ°í Ãæ½ÇÇÑ ¸®µå¸¦ Á¦°øÇÒ ¼ö Àֱ⠶§¹®¿¡ ¿¬±¸ÀÚµéÀÌ ¼±È£Çϸç, Ç¥Àû ¿µ¿ªÀÇ »ðÀÔ, °á½Ç ¹× µ¹¿¬º¯ÀÌ °ËÃâ¿¡ °¡Àå ÀûÇÕÇÑ ¹æ¹ýÀÔ´Ï´Ù. Áø´Ü ½ÇÇè½Ç¿¡¼­´Â Èñ±Í Áúȯ ¹× À¯Àü¼º ÁúȯÀÇ À¯ÀüÀÚ °Ë»ç¿¡ ³Î¸® »ç¿ëµÇ°í ÀÖÀ¸¸ç, SangerÀÇ ÃÖ¼ÒÇÑÀÇ µ¥ÀÌÅÍ Ãâ·ÂÀº ƯÈ÷ ÀÚ¿øÀÌ Á¦ÇÑµÈ È¯°æ¿¡¼­ ÀúÀå ¹× ºÐ¼®À» ´Ü¼øÈ­ÇÕ´Ï´Ù. ¶ÇÇÑ º¹ÀâÇÑ NGS ¿öÅ©Ç÷ο쿡 ºñÇØ ó¸® ½Ã°£ÀÌ ºü¸£´Ù´Â ÀåÁ¡µµ ÀÖ½À´Ï´Ù. À¯ÀüüÇÐ ½ÃÀåÀÌ ¼öÀÇÇÐ, ³ó¾÷, ¹Ì»ý¹°ÇÐ ºÐ¾ß·Î ´Ù¾çÈ­µÇ´Â °¡¿îµ¥, »ý¾î ½ÃÄö½ÌÀÇ °ß°í¼ºÀº ÇʼöÀûÀÎ º¸¿Ï ±â¼úÀÌ µÇ°í ÀÖ½À´Ï´Ù. ¸ð¼¼°ü Àü±â¿µµ¿ ½Ã½ºÅÛ¿¡ ´ëÇÑ ÀûÀÀ¼º°ú ±âÁ¸ ½ÇÇè½Ç ÀÎÇÁ¶ó¿ÍÀÇ ÅëÇÕ¼ºÀº ±âÁ¸ »ç¿ë »ç·Ê¿Í »õ·Î¿î »ç¿ë »ç·Ê ¸ðµÎ¿¡¼­ ±× Àû¿ëÀ» °è¼Ó Áö¿øÇϰí ÀÖ½À´Ï´Ù.

±â¼úÀº ¾î¶»°Ô »ý¾î ½ÃÄö½ÌÀÇ Á¤È®¼º°ú Á¢±Ù¼ºÀ» Çâ»ó½Ã۴°¡?

DNA ÃßÃâ, PCR Ŭ¸°¾÷ ¹× ¹ÝÀÀ ÁغñÀÇ ÀÚµ¿È­´Â ¼öÀÛ¾÷À¸·Î ÀÎÇÑ ½Ç¼ö¸¦ ÃÖ¼ÒÈ­ÇÏ°í ½Ã·á ó¸®ÀÇ È¿À²¼ºÀ» Çâ»ó½ÃÄ×À¸¸ç, DNA ÃßÃâ, PCR Ŭ¸°¾÷ ¹× ¹ÝÀÀ ÁغñÀÇ ÀÚµ¿È­´Â ¼öÀÛ¾÷À¸·Î ÀÎÇÑ ½Ç¼ö¸¦ ÃÖ¼ÒÈ­ÇÏ°í ½Ã·á ó¸®ÀÇ È¿À²¼ºÀ» Çâ»ó½ÃÄ×½À´Ï´Ù. ¿°·á Å͹̳×ÀÌÅÍ È­ÇÐ ¹× ¸ð¼¼°ü Àü±â¿µµ¿ ½Ã½ºÅÛÀÇ °³¼±À¸·Î ½ÅÈ£ÀÇ ¼±¸íµµ, ¼Óµµ ¹× µ¥ÀÌÅÍ ºÐÇØ´ÉÀÌ Çâ»óµÇ¾ú½À´Ï´Ù. ¼ÒÇü º¥Ä¡Å¾ ½ÃÄö¼­·Î ¼Ò±Ô¸ð ½ÇÇè½ÇÀ̳ª Ŭ¸®´Ð¿¡¼­ ºÐ»êÇü ½ÃÄö½ÌÀÌ °¡´ÉÇØÁ³½À´Ï´Ù. ¶ÇÇÑ, Ŭ¶ó¿ìµå ±â¹Ý ¹ÙÀÌ¿ÀÀÎÆ÷¸Åƽ½º Ç÷§Æû°úÀÇ ÅëÇÕÀ¸·Î µ¥ÀÌÅÍ ºÐ¼®, ÇØ¼®, º¸°í¼­ ÀÛ¼º¿¡ Àü¹®°¡°¡ ¾Æ´Ï¾îµµ »ç¿ëÇÒ ¼ö ÀÖ°Ô µÇ¾úÀ¸¸ç, AI ÅøÀ» »ç¿ëÇÏ¿© Àúºóµµ º¯ÀÌü¸¦ º¸´Ù ¾ÈÁ¤ÀûÀ¸·Î °ËÃâÇÒ ¼ö ÀÖ°Ô µÇ¾ú½À´Ï´Ù. ½Ã¾àÀÇ ¼ÒÇüÈ­´Â ½Ã·á´ç ºñ¿ë Àý°¨¿¡ µµ¿òÀÌ µÇ°í, ¿ÀÇ ¼Ò½º ½ÇÇè Àåºñ´Â ±³À° ±â°ü¿¡¼­ Àúºñ¿ëÀ¸·Î µµÀÔÇÒ ¼ö ÀÖµµ·Ï µ½½À´Ï´Ù. ½Ã·áÀÇ ¹ÙÄÚµå űëÀº ´õ ³ôÀº ¼öÁØÀÇ ´ÙÁßÈ­¸¦ °¡´ÉÇÏ°Ô ÇÏ¿© ½ÇÇè½ÇÀÇ »ý»ê¼ºÀ» Çâ»ó½Ãŵ´Ï´Ù. ¶ÇÇÑ, ½Ç½Ã°£ ¸ð´ÏÅ͸µ µµ±¸´Â ¸ðµç ´Ü°è¿¡¼­ ǰÁú °ü¸®¸¦ º¸ÀåÇÕ´Ï´Ù. ±× °á°ú, »ý¾î ½ÃÄö½ÌÀº ´õ ÀÌ»ó ´Ü¼øÇÑ ¼öÀÛ¾÷ ½ÇÇè½Ç ÀýÂ÷°¡ ¾Æ´Ñ, º¸´Ù ±¤¹üÀ§ÇÑ À¯ÀüüÇÐ »ýŰ迡 ÀûÇÕÇÑ ¹ÝÀÚµ¿È­µÈ Áö´ÉÇü Ç÷§ÆûÀ¸·Î ÁøÈ­Çϰí ÀÖ½À´Ï´Ù.

»ý¾î ½ÃÄö½Ì ¼ö¿ä°¡ °¡Àå ºü¸£°Ô Áõ°¡Çϰí ÀÖ´Â ºÐ¾ß´Â?

»ý¾î ½ÃÄö½ÌÀº Á¤È®¼º°ú È®ÀÎÀÌ °¡Àå Áß¿äÇÑ Æ¯Á¤ »ê¾÷¿¡¼­ »õ·Î¿î ¼ö¿ä°¡ ¹ß»ýÇϰí ÀÖ½À´Ï´Ù. ÀÓ»ó Áø´Ü¿¡¼­´Â ƯÈ÷ ¾Ï ¼ÒÀÎ ¹× Èñ±Í Áúȯ ÆÐ³Î¿¡¼­ »ý½Ä¼¼Æ÷ °è¿­ º¯ÀÌ È®ÀÎ °Ë»ç¿¡ ÀÚÁÖ »ç¿ëµË´Ï´Ù. ¾à¸®À¯ÀüüÇп¡¼­´Â Á¤È®ÇÑ À¯ÀüÇü ºÐ¼®ÀÌ ¸ÂÃãÇü Ä¡·á¿¡ ÇʼöÀûÀ̸ç, ±× ¿ªÇÒÀÌ È®´ëµÇ°í ÀÖ½À´Ï´Ù. ³ó¾÷À¯ÀüüÇеµ ¼ºÀå ºÐ¾ß·Î, ÀÛ¹°ÀÇ À¯ÀüÀÚÇü ÆÇº°, ÇüÁú È®ÀÎ, À°Á¾ ÇÁ·Î±×·¥¿¡ Ȱ¿ëµÇ°í ÀÖ½À´Ï´Ù. ¹Ì»ý¹°Çп¡¼­´Â º´¿øÃ¼ µ¿Á¤, Ç×»ýÁ¦ ³»¼º ºÐ¼®, ÇÃ¶ó½º¹Ìµå °ËÁõ¿¡ »ç¿ëµÇ°í ÀÖ½À´Ï´Ù. ¼öÀÇÇп¡¼­´Â Ç÷ÅëÀÌ ÀÖ´Â µ¿¹°ÀÇ À¯ÀüÀÚ °Ë»ç ¹× Áúº´ ÃßÀûÀ» À§ÇØ Á¡Á¡ ´õ ¸¹Àº ¼öÀÇÇÐÀÚµéÀÌ ½Ì°Å¸¦ »ç¿ëÇϰí ÀÖ½À´Ï´Ù. ¹ýÀÇÇÐ ¿¬±¸¼Ò¿¡¼­´Â °íǰÁúÀÇ ¸®µå Ãâ·ÂÀ¸·Î ÀÎÇØ ¹ÌÅäÄܵ帮¾Æ DNA ºÐ¼®¿¡ ÀÌ ¹æ¹ýÀ» °è¼Ó »ç¿ëÇϰí ÀÖ½À´Ï´Ù. ±³À° ±â°ü¿¡¼­µµ ½Å·Ú¼º°ú »ç¿ë ÆíÀǼº ¶§¹®¿¡ ½ÃÄö½ÌÀÇ ±âÃʸ¦ ¹è¿ì´Â ÇлýµéÀÇ ±³À°¿¡ Sanger ½Ã½ºÅÛÀ» »ç¿ëÇϰí ÀÖ½À´Ï´Ù. °è¾à ¿¬±¸ ±â°ü(CRO)¿¡ ´ëÇÑ ½ÃÄö½Ì ¼­ºñ½º ¾Æ¿ô¼Ò½ÌÀÇ Áõ°¡´Â ½ÃÀåÀÇ ¾ÈÁ¤ÀûÀÎ ¼ö¿ä¸¦ ´õ¿í ÃËÁøÇϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ºÐ¾ß °íÀ¯ÀÇ ¿ä±¸»çÇ×Àº Çö´ë À¯ÀüüÇп¡¼­ ±âÃÊ ±â¼ú·Î¼­ SangerÀÇ °íÀ¯ÇÑ ¿ªÇÒÀ» °­Á¶Çϰí ÀÖ½À´Ï´Ù.

»ý¾î ½ÃÄö½Ì ½ÃÀåÀÇ ¼ºÀåÀº ¸î °¡Áö ¿äÀο¡ ÀÇÇØ ¹ß»ýÇÕ´Ï´Ù...

»ý¾î ½ÃÄö½Ì ½ÃÀåÀÇ È®´ë´Â Áö¼ÓÀûÀÎ ±â¼úÀû ¸Å·Â°ú º¯È­ÇÏ´Â ¾÷°è ´ÏÁîÀÇ °áÇÕ¿¡ ÀÇÇØ µÞ¹ÞħµÇ°í ÀÖ½À´Ï´Ù. ƯÈ÷ Á¤¹ÐÀÇ·á¿¡¼­ µ¿¹ÝÁø´ÜÀÌ È®»êµÊ¿¡ µû¶ó ÀÓ»ó Áø´Ü¿¡¼­ ½Å·ÚÇÒ ¼ö ÀÖ´Â È®ÀÎ °Ë»ç¿¡ ´ëÇÑ ¼ö¿ä°¡ Áö¼ÓÀûÀ¸·Î Áõ°¡Çϰí ÀÖ½À´Ï´Ù. Çаè¿Í Á¤ºÎ ±â°üÀÇ ¿¬±¸ ÀÌ´Ï¼ÅÆ¼ºê Áõ°¡µµ ½ÃÀå È®´ë¿¡ ¹ÚÂ÷¸¦ °¡Çϰí ÀÖ½À´Ï´Ù. ºñ¿ë È¿À²¼º°ú ¼³Ä¡ÀÇ ¿ëÀ̼ºÀ¸·Î ÀÎÇØ Sanger´Â ƯÈ÷ °³¹ßµµ»ó±¹ÀÇ Àú󸮷® ½ÇÇè½Ç¿¡¼­ ¼±Åõǰí ÀÖÀ¸¸ç, NGS µ¥ÀÌÅͼ¼Æ®ÀÇ º¹À⼺À¸·Î ÀÎÇØ ÃÖÁ¾ °ËÁõÀ» À§ÇØ Sanger ½ÃÄö½Ì¿¡ ´ëÇÑ ÀÇÁ¸µµ°¡ ³ô¾ÆÁö°í ÀÖ½À´Ï´Ù. ±ÔÁ¦ ±â°üÀº ÀÔÁõµÈ ÀçÇö¼º°ú Á¤È®¼ºÀ¸·Î ÀÎÇØ ½ÂÀÎ ½Ã ½Ì°Å µ¥ÀÌÅ͸¦ ¼±È£Çϰí ÀÖ½À´Ï´Ù. ½ÇÇè½Ç ÀÚµ¿È­ ¹× º¥Ä¡Å¾ ½ÃÄö½Ì Àåºñ¿¡ ´ëÇÑ Áö¼ÓÀûÀÎ ÅõÀÚ·Î ÀÎÇØ ±â¼úÀÇ È®À强ÀÌ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ½ÃÀåÀº º´¿ø, CRO, ºÐÀÚÁø´Ü ±â¾÷ °£ÀÇ Çù·Â °ü°è È®´ëÀÇ ÇýÅÃÀ» ´©¸®°í ÀÖ½À´Ï´Ù. Sanger ½ÃÄö½ÌÀº °¨¿°º´ °¨½Ã¿¡¼­ ½Ä¹° À°Á¾¿¡ À̸£±â±îÁö ±¤¹üÀ§ÇÑ À¯Àüü ŸŶÀÇ º¸¿ÏÀûÀÎ ¼Ö·ç¼ÇÀ¸·Î ¹øÃ¢Çϰí ÀÖ½À´Ï´Ù.

ºÎ¹®

À¯Çü(¼¦°Ç ½ÃÄö½Ì, Ÿ°Ù À¯ÀüÀÚ ½ÃÄö½Ì, ±âŸ À¯Çü), ¿ëµµ(Áø´Ü, ¸ÂÃãÇü ÀÇ·á, ¹ýÀÇÇÐ, ±âŸ ¿ëµµ), ÃÖÁ¾ ¿ëµµ(Á¤ºÎ ¿¬±¸±â°ü, Áø´Ü ½ÇÇè½Ç, Á¦¾à¡¤¹ÙÀÌ¿ÀÅ×Å©³î·¯Áö ±â¾÷, ±âŸ ÃÖÁ¾ ¿ëµµ)

Á¶»ç ´ë»ó ±â¾÷ »ç·Ê(ÃÑ 42°³»ç)

°ü¼¼ ¿µÇâ °è¼ö

Global Industry Analysts´Â º»»çÀÇ ±¹°¡, Á¦Á¶°ÅÁ¡, ¼öÃâÀÔ(¿ÏÁ¦Ç° ¹× OEM)À» ±â¹ÝÀ¸·Î ±â¾÷ÀÇ °æÀï·Â º¯È­¸¦ ¿¹ÃøÇϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ º¹ÀâÇÏ°í ´Ù¸éÀûÀÎ ½ÃÀå ¿ªÇÐÀº ÀÎÀ§ÀûÀÎ ¸ÅÃâ¿ø°¡ Áõ°¡, ¼öÀͼº °¨¼Ò, °ø±Þ¸Á ÀçÆí µî ¹Ì½ÃÀû ¹× °Å½ÃÀû ½ÃÀå ¿ªÇÐ Áß¿¡¼­µµ ƯÈ÷ °æÀï»çµé¿¡°Ô ¿µÇâÀ» ¹ÌÄ¥ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

Global Industry Analysts´Â ¼¼°è ÁÖ¿ä ¼ö¼® ÀÌÄÚ³ë¹Ì½ºÆ®(1,4,949¸í), ½ÌÅ©ÅÊÅ©(62°³ ±â°ü), ¹«¿ª ¹× »ê¾÷ ´Üü(171°³ ±â°ü)ÀÇ Àü¹®°¡µéÀÇ ÀǰßÀ» ¸é¹ÐÈ÷ °ËÅäÇÏ¿© »ýŰ迡 ¹ÌÄ¡´Â ¿µÇâÀ» Æò°¡ÇÏ°í »õ·Î¿î ½ÃÀå Çö½Ç¿¡ ´ëÀÀÇϰí ÀÖ½À´Ï´Ù. ¸ðµç ÁÖ¿ä ±¹°¡ÀÇ Àü¹®°¡¿Í °æÁ¦ÇÐÀÚµéÀÌ °ü¼¼¿Í ±×°ÍÀÌ ÀÚ±¹¿¡ ¹ÌÄ¡´Â ¿µÇâ¿¡ ´ëÇÑ ÀǰßÀ» ÃßÀû Á¶»çÇϰí ÀÖ½À´Ï´Ù.

Global Industry Analysts´Â ÀÌ·¯ÇÑ È¥¶õÀÌ ÇâÈÄ 2-3°³¿ù ³»¿¡ ¸¶¹«¸®µÇ°í »õ·Î¿î ¼¼°è Áú¼­°¡ º¸´Ù ¸íÈ®ÇÏ°Ô È®¸³µÉ °ÍÀ¸·Î ¿¹»óÇϰí ÀÖÀ¸¸ç, Global Industry Analysts´Â ÀÌ·¯ÇÑ »óȲÀ» ½Ç½Ã°£À¸·Î ÃßÀûÇϰí ÀÖ½À´Ï´Ù.

2025³â 4¿ù : Çù»ó ´Ü°è

À̹ø 4¿ù º¸°í¼­¿¡¼­´Â °ü¼¼°¡ ¼¼°è ½ÃÀå Àüü¿¡ ¹ÌÄ¡´Â ¿µÇâ°ú Áö¿ªº° ½ÃÀå Á¶Á¤¿¡ ´ëÇØ ¼Ò°³ÇÕ´Ï´Ù. ´ç»çÀÇ ¿¹ÃøÀº °ú°Å µ¥ÀÌÅÍ¿Í ÁøÈ­ÇÏ´Â ½ÃÀå ¿µÇâ¿äÀÎÀ» ±â¹ÝÀ¸·Î ÇÕ´Ï´Ù.

2025³â 7¿ù : ÃÖÁ¾ °ü¼¼ Àç¼³Á¤

°í°´´Ôµé²²´Â °¢ ±¹°¡º° ÃÖÁ¾ ¸®¼ÂÀÌ ¹ßÇ¥µÈ ÈÄ 7¿ù¿¡ ¹«·á ¾÷µ¥ÀÌÆ® ¹öÀüÀ» Á¦°øÇØ µå¸³´Ï´Ù. ÃÖÁ¾ ¾÷µ¥ÀÌÆ® ¹öÀü¿¡´Â ¸íÈ®ÇÏ°Ô Á¤ÀÇµÈ °ü¼¼ ¿µÇ⠺м®ÀÌ Æ÷ÇԵǾî ÀÖ½À´Ï´Ù.

»óÈ£ ¹× ¾çÀÚ °£ ¹«¿ª°ú °ü¼¼ÀÇ ¿µÇ⠺м®:

¹Ì±¹ <> Áß±¹ <> ¸ß½ÃÄÚ <> ij³ª´Ù <> EU <> ÀϺ» <> Àεµ <> ±âŸ 176°³±¹

¾÷°è ÃÖ°íÀÇ ÀÌÄÚ³ë¹Ì½ºÆ® : Global Industry AnalystsÀÇ Áö½Ä ±â¹ÝÀº ±¹°¡, ½ÌÅ©ÅÊÅ©, ¹«¿ª ¹× »ê¾÷ ´Üü, ´ë±â¾÷, ±×¸®°í ¼¼°è °è·® °æÁ¦ »óȲÀÇ Àü·Ê ¾ø´Â ÆÐ·¯´ÙÀÓ ÀüȯÀÇ ¿µÇâÀ» °øÀ¯ÇÏ´Â ºÐ¾ßº° Àü¹®°¡ µî °¡Àå ¿µÇâ·Â ÀÖ´Â ¼ö¼® ÀÌÄÚ³ë¹Ì½ºÆ®¸¦ Æ÷ÇÔÇÑ 14,949¸íÀÇ ÀÌÄÚ³ë¹Ì½ºÆ®¸¦ ÃßÀûÇϰí ÀÖ½À´Ï´Ù. 16,491°³ ÀÌ»óÀÇ º¸°í¼­ ´ëºÎºÐ¿¡ ¸¶ÀϽºÅæ¿¡ ±â¹ÝÇÑ 2´Ü°è Ãâ½Ã ÀÏÁ¤ÀÌ Àû¿ëµÇ¾î ÀÖ½À´Ï´Ù.

¸ñÂ÷

Á¦1Àå Á¶»ç ¹æ¹ý

Á¦2Àå ÁÖ¿ä ¿ä¾à

Á¦3Àå ½ÃÀå ºÐ¼®

Á¦4Àå °æÀï

KSM
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

Global Sanger Sequencing Market to Reach US$8.9 Billion by 2030

The global market for Sanger Sequencing estimated at US$3.4 Billion in the year 2024, is expected to reach US$8.9 Billion by 2030, growing at a CAGR of 17.5% over the analysis period 2024-2030. Shotgun Sequencing, one of the segments analyzed in the report, is expected to record a 16.3% CAGR and reach US$5.4 Billion by the end of the analysis period. Growth in the Targeted Gene Sequencing segment is estimated at 19.1% CAGR over the analysis period.

The U.S. Market is Estimated at US$894.2 Million While China is Forecast to Grow at 16.6% CAGR

The Sanger Sequencing market in the U.S. is estimated at US$894.2 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$1.4 Billion by the year 2030 trailing a CAGR of 16.6% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 15.9% and 15.3% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 13.0% CAGR.

Global "Sanger Sequencing" Market - Key Trends & Drivers Summarized

Why Does Sanger Sequencing Remain Relevant in a Genomics-Driven World?

Despite the rise of next-generation sequencing (NGS) platforms, Sanger sequencing retains its relevance due to its unparalleled accuracy, simplicity, and cost-effectiveness for specific applications. It remains the gold standard for sequence validation, single-gene diagnostics, and small-scale research projects. This method is highly valued in clinical genomics for confirming variants identified through high-throughput methods. Researchers favor Sanger sequencing for its ability to deliver long, high-fidelity reads, often up to 1000 base pairs, which are ideal for detecting insertions, deletions, or mutations in targeted regions. Diagnostic labs use it extensively for genetic testing in rare diseases and hereditary conditions. Sanger’s minimal data output also simplifies storage and analysis, especially in resource-limited settings. It offers the added advantage of faster turnaround times when compared to complex NGS workflows. As the genomics market diversifies into veterinary, agricultural, and microbiological fields, Sanger sequencing’s robustness makes it an essential complementary technology. Its adaptability to capillary electrophoresis systems and integration with existing lab infrastructure continues to support its application across both legacy and emerging use cases.

How Is Technology Enhancing the Precision and Accessibility of Sanger Sequencing?

Recent advancements are significantly refining the Sanger sequencing workflow, reducing costs and improving throughput. Automation in DNA extraction, PCR cleanup, and reaction preparation has minimized manual errors and increased sample handling efficiency. Improvements in dye-terminator chemistry and capillary electrophoresis systems have enhanced signal clarity, speed, and data resolution. Compact, benchtop sequencers now allow decentralized sequencing in smaller labs and clinics. Integration with cloud-based bioinformatics platforms has also made data analysis, interpretation, and reporting more accessible to non-specialists. AI tools are being used to detect low-frequency variants with greater confidence. Reagent miniaturization is helping reduce per-sample costs, and open-source labware is facilitating low-cost adoption in educational institutions. Barcode tagging of samples is enabling higher levels of multiplexing, increasing lab productivity. Furthermore, real-time monitoring tools are ensuring quality control at every stage. As a result, Sanger sequencing is no longer just a manual lab procedure; it is evolving into a semi-automated, intelligent platform that fits neatly into the broader genomics ecosystem.

In Which Fields Is the Demand for Sanger Sequencing Growing Most Rapidly?

Sanger sequencing is experiencing renewed demand in specific verticals where accuracy and confirmation are paramount. In clinical diagnostics, it's frequently used for confirmatory testing of germline mutations, especially in cancer predisposition and rare disease panels. Its role is expanding in pharmacogenomics, where precise genotyping is essential for tailored therapies. Agricultural genomics is another growing field, with Sanger used for crop genotyping, trait confirmation, and breeding programs. In microbiology, it is employed for pathogen identification, antibiotic resistance analysis, and plasmid verification. Veterinary medicine is increasingly adopting Sanger for genetic screening in pedigree animals and disease tracking. Forensic labs continue to use the method for mitochondrial DNA analysis due to its high-quality read output. Educational institutions also rely on Sanger systems for training students in sequencing fundamentals due to their reliability and ease of use. The rise in outsourcing of sequencing services to contract research organizations (CROs) is further supporting steady market demand. These sector-specific requirements highlight Sanger’s unique role as a foundational technology in modern genomics.

The Growth In The Sanger Sequencing Market Is Driven By Several Factors...

The expansion of the Sanger sequencing market is underpinned by a blend of enduring technological appeal and shifting industry needs. Demand for high-confidence confirmatory testing in clinical diagnostics is sustaining its usage, especially as companion diagnostics gain traction in precision medicine. The increasing number of research initiatives in academic and government institutions is also fueling market expansion. Cost-effectiveness and ease of setup are making Sanger the method of choice for low-throughput labs, especially in developing regions. The growing complexity of NGS datasets has led to increased reliance on Sanger sequencing for final validation. Regulatory agencies prefer Sanger data for approvals due to its proven reproducibility and accuracy. Continued investments in lab automation and benchtop sequencing devices are making the technology more scalable. Moreover, the market is benefiting from growing collaborations between hospitals, CROs, and molecular diagnostic companies. With applications ranging from infectious disease surveillance to plant breeding, Sanger sequencing is thriving as a complementary solution in the broader genomic toolkit.

SCOPE OF STUDY:

The report analyzes the Sanger Sequencing market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Type (Shotgun Sequencing, Targeted Gene Sequencing, Other Types); Application (Diagnostics, Personalized Medicine, Forensics, Other Applications); End-Use (Government Research Institutes, Diagnostic Labs, Pharma & Biotech Companies, Other End-Uses)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; and Rest of Europe); Asia-Pacific; Rest of World.

Select Competitors (Total 42 Featured) -

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by artificially increasing the COGS, reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

We are diligently following expert opinions of leading Chief Economists (14,949), Think Tanks (62), Trade & Industry bodies (171) worldwide, as they assess impact and address new market realities for their ecosystems. Experts and economists from every major country are tracked for their opinions on tariffs and how they will impact their countries.

We expect this chaos to play out over the next 2-3 months and a new world order is established with more clarity. We are tracking these developments on a real time basis.

As we release this report, U.S. Trade Representatives are pushing their counterparts in 183 countries for an early closure to bilateral tariff negotiations. Most of the major trading partners also have initiated trade agreements with other key trading nations, outside of those in the works with the United States. We are tracking such secondary fallouts as supply chains shift.

To our valued clients, we say, we have your back. We will present a simplified market reassessment by incorporating these changes!

APRIL 2025: NEGOTIATION PHASE

Our April release addresses the impact of tariffs on the overall global market and presents market adjustments by geography. Our trajectories are based on historic data and evolving market impacting factors.

JULY 2025 FINAL TARIFF RESET

Complimentary Update: Our clients will also receive a complimentary update in July after a final reset is announced between nations. The final updated version incorporates clearly defined Tariff Impact Analyses.

Reciprocal and Bilateral Trade & Tariff Impact Analyses:

USA <> CHINA <> MEXICO <> CANADA <> EU <> JAPAN <> INDIA <> 176 OTHER COUNTRIES.

Leading Economists - Our knowledge base tracks 14,949 economists including a select group of most influential Chief Economists of nations, think tanks, trade and industry bodies, big enterprises, and domain experts who are sharing views on the fallout of this unprecedented paradigm shift in the global econometric landscape. Most of our 16,491+ reports have incorporated this two-stage release schedule based on milestones.

COMPLIMENTARY PREVIEW

Contact your sales agent to request an online 300+ page complimentary preview of this research project. Our preview will present full stack sources, and validated domain expert data transcripts. Deep dive into our interactive data-driven online platform.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

III. MARKET ANALYSIS

IV. COMPETITION

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â